Market Overview

J.P. Morgan Reinstates Underweight Rating on Myriad Over LT Outlook Concerns

Related MYGN
Myriad myPath Melanoma Test Reduced Indeterminate Cases By 76% And Changed Treatment In 35 % Of Cases
Myriad Publishes myRisk Hereditary Cancer Study In Cancer

J.P. Morgan analyst Tycho Peterson reinstated an Underweight rating and $25.00 price target on Myriad Genetics Inc. (NASDAQ: MYGN) following the period of restriction related to the $270 million acquisition of Crescendo.

Peterson commented, "Our concerns over the longer-term outlook for pricing and ability to hold share within the core BRCA (soon to be myRisk) business remain unchanged, as highlighted in our proprietary physician survey, while in the near-term, we acknowledge several offsets stemming from high short interest (~52%), ongoing share buybacks (3.2M shares in F2Q) and an increased focus on diversification (Crescendo, Prolaris, PARP inhibitors), which could provide downside protection over the next several quarters."

Shares of Myriad Genetics Inc. closed at $32.87 on Friday. The stock is currently up 2.25% at $33.61.

Latest Ratings for MYGN

DateFirmActionFromTo
Aug 2014Credit SuisseMaintainsNeutral
Jun 2014MacquarieMaintainsNeutral
May 2014Credit SuisseMaintainsNeutral

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: J.P. Morgan Tycho W. PetersonAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters